Instructions to Authors 2014

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research. The principal aim of IN VIVO is to provide prompt (print and online) publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

Ethical Policies and Standards. IN VIVO agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (link to: http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org (mail to: journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, GR-19014 Kapandriti, Attiki, GREECE.

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles published in 2014 are entitled to a complimentary online subscription of IN VIVO 2014. Requests should be addressed to the Editorial Office.

Copyright© 2014 International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
ANTICANCER RESEARCH is an independent international forum devoted to the rapid publication of original high quality articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months from acceptance are guaranteed.

ANTICANCER RESEARCH is published monthly by the International Institute of Anticancer Research and is available online with Stanford University HighWire Press.

For more information please visit our website www.ar.iiarjournals.org.

Editorial Office: International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19104, Greece. Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org.

IIAR website: www.iiar-anticancer.org

Selection of Recent Articles


Levonorgestrel-impregnated Intrauterine Device Reduces Occurrence of Hyperplastic Polyps: A Population-based Follow-up Cohort Study. A. MARIT, B. HVINGEL, A. ØRBO (Tromsø, Norway)

Impact of Epoetin beta on Anemia and Health-related Quality of Life in Cancer Patients: A Prospective Observational Study Using the Generic 15D Instrument. J. MAENPÄÄ, U. PUISTOLA, H. RISKA, H. SINTONEN, O. SAARNI, E. JUVONEN, P.-L. KELLOKUMPU-LEHTINEN (Tampere; Oulu; Turku, Finland)

Survival of Patients Undergoing Cytoreductive Surgery for Metastatic Renal Cell Carcinoma in the Targeted Therapy Era. M.R. ABERN, E. COSYREV, M. TSVIAN, E.M. MESSING, T.J. POLASCIK, A. DUDEK (Chicago, IL; Rochester, NY; Durham, NC, USA)

Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK (Graz, Austria)


Ascorbic Acid Induces either Differentiation or Apoptosis in MG-63 Osteosarcoma Lineage. M.T. VALENTI, M. ZANATTA, L. DONATELLI, G. VIVIANO, C. CAVALLINI, M.T. SCUPOLI, L. DALLE CARBONARE (Verona, Italy)


Evidence that Milepimidine is a Progesterone Receptor Antagonist, can Cross the Blood Brain Barrier and Provide Palliative Benefits for Glioblastoma Multiforme Grade IV. J.H. CHECK, C. WILSON, R. COHEN, M. SARUMI (Camden; Marlton, NJ, USA; Philadelphia, PA, USA)

HLA-A*02 in Relation to Outcome in Human Papillomavirus Positive Tonsillar and Base of Tongue Cancer. N. TERTIPIS, L. VILLABONA, C. NORDFORS, A. SÅMÅN, T. RAMQVIST, A. VLASTOS, G. MASUCCI, T. DALIANIS (Stockholm, Sweden)

Neamine Inhibits Oral Cancer Progression by Suppressing Angiogenin-mediated Angiogenesis and Cancer Cell Proliferation. K. KISHIMOTO, S. YOSHIDA, S. IBARAGI, N. YOSHIKOA, G.-F. HU, A. SASAKI (Okayama, Japan; Boston, MA, USA)

Inflammation-based Prognostic Score (mGPS) Predicts Biliary Stent Patency in Patients with Unresectable Malignant Biliary Obstruction. Y. IWASAKI, M. KATOH, J. KITA, M. SHIMODA, K. KUBOTA (Mibu, Tochigi, Japan)

The Association of Caveolin-1 Genotypes with Gastric Cancer in Taiwan. C.-H. LIN, C.-C. LIN, C.-W. TSAI, W.-S. CHANG, C.-W. YANG, D.-T. BAU (Taichung, Taiwan, ROC)


Clinical Trial of a 7-Peptide Cocktail Vaccine with Oral Chemotherapy for Metastatic Colorectal Cancer Patients. K. OKUNO, F. SUKEGAWA (Osaka-sayama, Osaka, Japan)


Novel Nucleosomics Serum Biomarkers for the Detection of Colorectal Cancer. S. HOLDENRIEDER, Y. DHARUMAN, M. HERZOG, K. HETTWER, K. SIMON, S. UHLIC, J. MICALEFF (Bonn; Dresden, Germany; Namur, Belgium)

High Levels of Wilms’ Tumor 1 (WT1) Expression were Associated with Aggressive Clinical Features in Ovarian Cancer. Z. LIU, K. YAMANOUCHI, T. OHTA, S. MATSUMURA, M. SEINO, V. SHRIDHAR, T. TAKAHASHI, K. TAKAHASHI, H. KURACHI (Yamagata, Japan; Rochester, MN, USA)

Synergistic Inhibition of HCC and Liver Cancer Stem Cell Proliferation by Targeting RAS/RAF/MEK and WNT/β-Catenin Pathways. R. GALUPPO, E. MAYNARD, M. SHAH, M.F. DAILY, C. CHEN, B.T. SPEAR, R. GEDALY (Lexington, KY, USA)
A Selection of Recent Papers


Crucial and Novel Cancer Drivers in a Mouse Model of Triple-Negative Breast Cancer. J.P.S. JOHNSON, P. KUMAR, M. KOULNIS, M. PATEL, K. SIMIN (Worcester, MA; Bethesda, MD; Scranton, PA; New York, NY, USA; Singapore, Singapore)

Cilia Gene Expression Patterns in Cancer. M. SHPAK, M.M. GOLDBERG, M.C. COWPERTHW AITE (Austin TX, USA)

MicroRNA-150 Is Up-regulated in Extranodal Marginal Zone Lymphoma of MALT Type. N. GEBAUER, J. KUBA, A. SENFT, A. SCHILLERT, V. BERNARD, C. THORNS (Lübeck, Germany)


Fucoidan-dependent Increased Membrane Component in HepG2: Effect of Fucoidan Is Not Due to Gene Expression. K. HAYAKAWA, T. NAGAMINE (Tokyo; Gunma, Japan)


A Novel Transmembrane Glycoprotein Cancer Biomarker Present in the X Chromosome. A.P. DELGADO, S. HAMID, P. BRANDAO, R. NARAYANAN (Boca Raton, FL, USA)

Rho Kinase Proteins Regulate Global miRNA Expression in Endothelial Cells. J.M. STILES, V. KURISETTY, D.C. MITCHELL, B.A. BRYAN (El Paso, TX, USA)

Gene Expression Profiling of Circulating Natural Killer Cells in Head and Neck Squamous Cell Carcinoma. A. BOTTCHER, J. OSTWALD, D. KOCZAN, R. KNECHT, B. KRAMP, S. DOMMERICH (Hamburg; Rostock; Berlin, Germany)


Isolation of Stem Cells Using Spheroids from Fresh Surgical Specimen: An Analytic Mini-review. I. AVITAL, A. STOJADINOVIC, H. WANG, C. MANNION, W.C.S. CHO, J. WANG, Y.G. MAN (Richmond, VA; Hackensack, NJ; Washington, DC, USA; Hangzhou, China; Hong Kong, Hong Kong)

Special 2014 Offers to Authors of IN VIVO

(These offers are open to all authors of articles published in IN VIVO 1987-2014 on a basis of priority and availability. Effective from January to December 2014).

Please complete and send this order form to:
IN VIVO, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece.

Special Subscription Order Form 2014

☐ I am one of the authors of the article published in IN VIVO Vol. ........, pp. ..........., year ...........

☐ Please enter my personal subscription to IN VIVO 2014 (Volume 28) at the special Author’s rate of Euro 190.00 (print or online).

☐ Please send me previous Volume No(s) .............. at Euro 108.00 (print) per volume.

☐ Please enter my personal combined 2014 subscription to IN VIVO (Volume 28) and ANTICANCER RESEARCH (Volume 34) at Euro 560.00 (print or online)

☐ Payment is enclosed.

☐ Please send me an invoice.

Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P., (Athens, Greece).

Name and address: ..................................................................................................................................................

Tel: .................................................................................................................................................................

Fax: .................................................................................................................................................................

Signature: ..........................................................................................................................................................

Date and signature: ..............................................................................................................................................
Effects of the Combined Use of a Dermal Substitute with a Cleansing Process in the Simulation of Autologous Skin: A Pilot Study. A. LUCARIELLO, M. CINELLI, A. DE NOVELLIS, C. NIKOLOPOULOS, V. ESPOSITO, G. GUERRA (Naples; Campobasso, Italy) ................................................................. 639

Combined Versus Monotherapy or Concurrent Therapy for Treatment of Thalassaemia. T.-S. SONG, Y.-W. HSIEH, C.-T. PENG, T.-L. CHEN, H.-Z. LEE, J.-G. CHUNG, M.-J. HOUR (Taichung; Taipei, Taiwan, ROC) ........................................................................................................................................ 645

Extradural Granulation Complicated by Chronic Suppurative Otitis Media with Cholesteatoma. C.H. JANG, Y.H. CHOI, E.S. JEON, H.C. YANG, Y.B. CHO (Gwawngiu, Republic of Korea)............................... 651

Inhibitory Action of Levocetirizine on the Production of Eosinophil Chemoattractants RANTES and Eotaxin In Vitro and In Vivo. A. KANEI, K. ASANO, K.-I. KANAI, A. FURUTA, K. SASAKI, H. SUZAKI (Tokyo; Yokohama, Japan) ........................................................................................................ 657


Errata ...................................................................................................................................................................... 673
Anti-inflammatory Potential of Rikkosan Based on IL-1β Network Through Macrophages to Oral Tissue Cells. N. HORIE, K. HASHIMOTO, S. HINO, T. KATO, T. SHIMOYAMA, T. KANEKO, K. KUSAMA, H. SAKAGAMI (Sakado; Kawagoe, Saitama; Tokyo, Japan) ................................................................. 563

Anti-UV Activity of Kampo Medicines and Constituent Plant Extracts: Re-evaluation with Skin Keratinocyte System. T. KATO, S. HINO, N. HORIE, T. SHIMOYAMA, T. KANEKO, K. KUSAMA, H. SAKAGAMI (Kawagoe, Saitama; Tokyo, Japan) ................................................................. 571

Plasma Homocysteine Concentrations in Novel Microminipigs. T. KAKIMOTO, A. OTSUKA, H. KAWAGUCHI, K. OGATA, A. TANIMOTO, H. KANOUCHI (Kagoshima; Nobeoka, Miyazaki, Japan) ................................................................. 579

Alpha-phellandrene, a Natural Active Monoterpen, Influences a Murine WEHI-3 Leukemia Model In Vivo by Enhancing Macrophage Phagocytosis and Natural Killer Cell Activity. J.-J. LIN, K.-W. LU, Y.-S. MA, N.-Y. TANG, P.-P. WU, C.-C. WU, H.-F. LU, J.-G. LIN, J.-G. CHUNG (Taichung; Kaohsiung; Tainan; Taipei, Taiwan, ROC) ................................................................. 583

Clinical Studies

Comparative Study of Prescribing Patterns of Tigecycline for Trial Patients versus Non-trial Patients. J.J. HORSCHT, J.B. ZIMMERMANN, M.A. WEIGAND, T. BRUCKNER, E.O. MARTIN, T. HOPPETICHY, S. SWOBODA (Heidelberg; Gießen, Germany) ................................................................. 589

Lateral Periodontal Cyst. R.E. FRIEDRICH, H.A. SCHEUER, J. ZUSTIN (Hamburg; Münster, Germany) ................................................................. 595

Successful Surgical Repair of Central Slip Rupture in Finger Extensor Tendon. Z. HOU, L. ZHAO, S. YU, B. XIAO, J. ZHOU (Yantai, Shandong, PR China) ................................................................. 599

Circulating Tumor Cells in Patients with Breast Cancer: Monitoring Chemotherapy Success. Z. UŠIAKOVÁ, V. MIKULOVÁ, D. PINTÉROVÁ, M. BRÝCHTA, J. VALČHÁŘ, M. KUBECOVÁ, P. TESAŘOVÁ, V. BOBEK, K. KOLŮŠTOVÁ (Prague, Czech Republic; Wrocław, Poland) ................................................................. 605

The Impact of Age and Sex Adjusted Body Mass Index (ISO-BMI) in Obese Versus Non-obese Children and Adolescents with Cholecystectomy. E. KIURU, H. KOKKI, P. JUVONEN, H. LINTULA, H. PAAJANEN, M. GISSLER, M. ESZKELINEN (Kuopio; Gothenburg, Sweden; Helsinki, Finland) ................................................................. 615


Indoleamine 2,3-dioxygenase and Immune Changes Under Antidepressive Treatment in Major Depression in Females. M. ZOGA, P. OULIS, S. CHATZIPANAGIOTOU, V.G. MASDRAKIS, P. PLIATSIKA, F. BOUFIDOU, S. FOTELI, C.R. SOLDATOS, C. NIKOLAOU, C. PAPAGEORGIOU (Athens, Greece) ................................................................. 633

Contents continued
Effects of Interactions Between Progesterone and Prostaglandin on Uterine Contractility in a Perfused Swine Uterus Model. J. KÜNZEL, K. GEISLER, T. MALTARIS, A. MÜLLER, I. HOFFMANN, H. SCHNEIDER, M.W. BECKMANN, R. DITTRICH, P.G. OPPELT (Erlangen, Germany).......................... 467

Osteogenic Differentiation of Mesenchymal Stem Cells in Fibrin-Hydroxyapatite Matrix in a 3-Dimensional Mesh Scaffold. O. JUNG, H. HANKEN, R. SMEETS, P. HARTJEN, R.E. FRIEDRICH, B. SCHWAB, A. GRÖBE, M. HEILAND, A. AL-DAM, W. EICHHORN, S. SEHNER, A. KOLK, M. WÖLTJE, J.M. STEIN (Hamburg; Aachen; Munich, Germany)................................................................. 477

Melatonin Does Not Affect Oxidative/Inflammatory Biomarkers in a Closed-Chest Porcine Model of Acute Myocardial Infarction. N.L. HALLADIN, S. EKELØF, S.E. JENSEN, J. AARØE, B. KJÆRGAARD, P.M.H. HEEGAARD, J. LYKKEFELDT, J. ROSENBERG, I. GÖGENUR (Herlev; Aalborg; Frederiksberg C, Denmark)........................................................................ 483

Anti-inflammatory Effects of Polihexanide and Polyethylene Glycol in an In Vitro Study in Chronic Rhinosinusitis. R. BIRK, J. GROSSBAIER, C. ADERHOLD, J. STERN-STRÄTER, K. HÖRMANN, A. SAUTER, J.U. SOMMER (Mannheim, Germany).......................................................................................... 489


Human Conchal Cartilage and Temporal Fascia: An Evidence-based Roadmap from Rhinoplasty to an In Vivo Study and Beyond. A.M. CIMPEAN, Z. CRĂINICEANU, D. MIHAILEVICI, T. BRATU, M. RAICA (Timisoara, Romania)........................................................................................................ 505

Suppressive Activity of Quercetin on the Production of Eosinophil Chemoattractants from Eosinophils In Vitro. M. SAKAI-KASHIWABARA, S. ABE, K. ASANO (Yokohama, Japan)............................................................................................................. 515

Determination of the LD₉₀ of Acridine Orange via Intravenous Administration in Mice in Preparation for Clinical Application to Cancer Therapy. T. NAKAMURA, K. KUSUZAKI, T. MATSUBARA, A. MATSUMINE, K. ASANUMA, H. SATONAKA, A. UCHIDA, A. SUDO (Mie; Kyoto; Ise, Japan)................................................................. 523

Structural Chromatin Alterations in Peripheral Blood Leukocytes of Alcohol-dependent Individuals During Detoxification Therapy. M. CHRYSANTHOU PITEROU, I. KLOUKINA PANTAZIDOU, S. HAVAKI, J. LIAPPAS, M. ISSIDORIDES RADOVITCH (Athens, Greece).................................................................................. 529

Proliferative and Apoptotic Activity of Glioblastoma Multiforme Cells Cultured on In Ovo Model. K. URBAŃSKA, J. SOKOŁOWSKA, M. SZMIDT, P. SYSA (Warsaw, Poland)............................................................................................................. 541

Cytotoxicity and Pro-Inflammatory Action of Chemo-Mechanical Caries-removal Agents Against Oral Cells. R. GARCIA-CONTRERAS, R.J. SCougall-VILCHIS, R. CONTRERAS-BULNES, Y. KANDA, H. NAKAJIMA, H. SAKAGAMI (Toluca, Mexico; Sakado, Saitama, Japan).................................................................................. 549

Exposure to Submicron Particles (PM₁₀) from Diesel Exhaust and Pollen Allergens of Human Lung Epithelial Cells Induces Morphological Changes of Mitochondria Tonofilaments and Rough Endoplasmic Reticulum. G. MAZZARELLA, A. LUCARIELLO, A. BIANCO, C. CALABRESE, T. THANASSOULAS, L. SAVARESE, A. FIUMARELLA, V. ESPOSITO, A. DE LUCA (Naples; Campobasso, Italy)................................................................................... 557